Autoimmune hemolytic anemia
MONDO:0020108Autoimmune hemolytic anemia (AIHA) is an autoimmune disorder in which various types of auto-antibodies are directed against red blood cells causing their survival to be shortened and resulting in hemolytic anemia.
Also known as: AHA, AIHA, Anemia, Hemolytic, Acquired Autoimmune, autoimmune haemolytic anemia, autoimmune hemolytic anemia, acquired autoimmune hemolytic anaemia, acquired autoimmune hemolytic anemia, anaemia hemolytic autoimmune
115 clinical trials for this condition and its sub-types, 49 tagged with Autoimmune hemolytic anemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Autoimmune hemolytic anemia
-
Autoimmune hemolytic anemia, warm type 29 trials
-
Evans syndrome 19 trials
-
Autoimmune hemolytic anemia, cold type 2 trials · 15 incl. sub-types
2 sub-types
- Cold agglutinin disease 14 trials
- Paroxysmal cold hemoglobinuria 0 trials
-
Neonatal autoimmune hemolytic anemia 0 trials
-
Experimental immune therapy for stubborn anemia shows early promise but trial stalls
Disease control Stopped earlyThis early-phase trial tested whether low doses of interleukin-2 (IL-2), a protein that helps regulate the immune system, could help people with warm autoimmune hemolytic anemia (wAHAI) whose disease did not improve with standard steroid treatment. The study planned to give four …
Phase 1/2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental drug tested for stubborn blood disorder – but trial cut short
Disease control Stopped earlyThis early-phase study tested the drug Linperlisib in just 4 adults with autoimmune hemolytic anemia (AIHA) whose disease did not improve after at least two prior treatments. The goal was to see if the drug could help control the disease by targeting a key immune pathway. However…
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Promising drug for Post-Transplant blood issues falls short in early trial
Disease control Stopped earlyThis study tested a drug called fostamatinib to help people whose blood cell counts drop after a stem cell transplant. The goal was to see if the drug could raise red blood cells or platelets without needing transfusions. The trial was stopped early after enrolling only one perso…
Phase 2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Experimental drug iptacopan tested for rare blood disorders
Disease control Stopped earlyThis study tested an experimental drug called iptacopan in people with two rare blood disorders: immune thrombocytopenia (ITP) and cold agglutinin disease (CAD). The goal was to see if the drug could improve platelet counts in ITP or hemoglobin levels in CAD. The trial was termin…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental drug for rare blood disorder tested for long-term safety
Disease control Stopped earlyThis study tested the long-term safety of a drug called SAR445088 in people with cold agglutinin disease, a rare condition where the immune system attacks red blood cells. Only 9 participants were enrolled, and the study was terminated early. The goal was to see if the drug is sa…
Phase 1 • Sponsor: Bioverativ, a Sanofi company • Aim: Disease control
Last updated Jun 26, 2026 16:38 UTC